e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Novel studies on bronchodilators and cough
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Functional respiratory imaging (FRI) and lung function assessment of glycopyrronium/formoterol fumarate dihydrate fixed-dose combination delivered using novel Co-Suspension Delivery Technology (GFF MDI) in COPD
W. De Backer (Edegem (Antwerp), Belgium)
Source:
International Congress 2017 – Novel studies on bronchodilators and cough
Session:
Novel studies on bronchodilators and cough
Session type:
Oral Presentation
Number:
4404
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. De Backer (Edegem (Antwerp), Belgium). Late Breaking Abstract - Functional respiratory imaging (FRI) and lung function assessment of glycopyrronium/formoterol fumarate dihydrate fixed-dose combination delivered using novel Co-Suspension Delivery Technology (GFF MDI) in COPD. 4404
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
A 12-year-old male child with fever, productive cough and sudden onset paralysis
A 41-year-old male with cough productive of yellow sputum and worsening breathlessness
Related content which might interest you:
Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI).
Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update
Year: 2019
Z7200 versus Symbicort® Turbohaler®: A pharmacodynamic evaluation of the acute effects using functional respiratory imaging (FRI)
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using Functional Respiratory Imaging (FRI).
Source: International Congress 2019 – Imaging in respiratory disease: novel technologies in 2019
Year: 2019
LATE-BREAKING ABSTRACT: Pulmonary deposition of a novel LAMA/LABA Co-Suspension[sup][trade][/sup] technology glycopyrronium/formoterol (GFF) MDI in healthy subjects (PT003020)
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016
Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients (pts)
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Lung deposition of extrafine inhaled corticosteroid (ICS)-containing fixed combinations drug in COPD patients using Functional Respiratory Imaging (FRI).
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018
Effect of nebulizer system on tobramycin concentration using functional respiratory imaging (FRI)
Source: International Congress 2016 – Cystic fibrosis: various aspects
Year: 2016
Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Late Breaking Abstract - Factors associated with health-status of COPD patients on Dry Powder Inhaler (DPI) maintenance therapy
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis)
Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD
Year: 2018
Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts)
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Edry™ an innovative dry powder technology evaluated via functional respiratory imaging (FRI)
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Comparison between electronic and paper versions of the Evaluating Respiratory Symptoms in COPD (E-RS) and the COPD Assessment Test (CAT).
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017
Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study)
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019
Efficacy and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (GFF MDI) delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe COPD
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept